Rxwire
In the news · 48h FDA 35 Eli Lilly 17 Roche 11 Johnson & Johnson 7 Merck & Co. (MSD) 6 AstraZeneca 4 Bayer 2 Sanofi 2
Deals & business · first seen 3h ago, updated 3h ago

Another top IPO: Adarx’s $446M to advance clinical siRNA assets

1 outlet

A preview of the next edition of BioWorld, Sept. 25, 2026

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

  1. BioWorld Articles
    Another top IPO: Adarx’s $446M to advance clinical siRNA assets